XML 48 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Significant Agreements (Details)
$ in Thousands
3 Months Ended
Sep. 26, 2022
USD ($)
treatment
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Emergent | TEMBEXA | Base Period          
Schedule of Investments          
Up-front cash payment $ 238,000        
Quantity royalty rate, trigger (treatments) | treatment 1,700,000        
Emergent | TEMBEXA | Base Period | Non- United States          
Schedule of Investments          
Gross profit royalty rate (as a percent) 15.00%        
Emergent | TEMBEXA | Base Period | United States          
Schedule of Investments          
Gross profit royalty rate (as a percent) 20.00%        
Emergent | BARDA | Base Period          
Schedule of Investments          
Maximum milestone proceeds upon the exercise of options $ 124,000        
SymBio Pharmaceuticals | Scenario, Plan          
Schedule of Investments          
Deferred revenue $ 12,500        
Emergent Biodefense Operations Lansing LLC          
Schedule of Investments          
Revenue recognized   $ 0 $ 200    
Ohara Pharmaceutical Co., Ltd.          
Schedule of Investments          
License agreement, nonrefundable regulatory milestone payment to be received         $ 2,500
CR Sanjui | Oncoceutics, Inc.          
Schedule of Investments          
Payment to be received upon achievement of milestones       $ 5,000